Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > It Was Just A Typo

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Jun 27, 2024 4:56pm

103 Views

Post# 36109706

RE:RE:RE:RE:RE:RE:RE:RE:RE:It Was Just A Typo

The registered agent is responsible for receiving all official documents related to the company they represent, notifying them about the receipt and passing the documents to designated persons within an organization. Registered agents also keep official records of the company at their registered address as required by law.

By implication, along with above, the registered agent is responsible for the accuracy of the said documents

https://www.athennian.com/post/what-is-a-registered-agent

<< Previous

Bullboard Posts

Next >>

10 common investing mistakes to avoid